Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Debt Ratio (2022 - 2025)

NewAmsterdam Pharma's Debt Ratio history spans 4 years, with the latest figure at 0.07 for Q4 2025.

  • For Q4 2025, Debt Ratio rose 71.59% year-over-year to 0.07; the TTM value through Dec 2025 reached 0.07, up 71.59%, while the annual FY2025 figure was 0.07, 71.59% up from the prior year.
  • Debt Ratio for Q4 2025 was 0.07 at NewAmsterdam Pharma, up from 0.06 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.07 in Q4 2025 and bottomed at 0.01 in Q4 2022.
  • The 4-year median for Debt Ratio is 0.04 (2024), against an average of 0.04.
  • The largest annual shift saw Debt Ratio skyrocketed 373.77% in 2023 before it plummeted 57.53% in 2025.
  • A 4-year view of Debt Ratio shows it stood at 0.01 in 2022, then surged by 373.77% to 0.04 in 2023, then increased by 19.77% to 0.04 in 2024, then surged by 71.59% to 0.07 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Debt Ratio are 0.07 (Q4 2025), 0.06 (Q3 2025), and 0.03 (Q2 2025).